Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Wendell Wierenga also recently made the following trade(s):

• On Monday, October 27th, Wendell Wierenga sold 4,375 shares of Cytokinetics stock. The stock was sold at an average price of $58.68, for a total transaction of $256,725.00.

Cytokinetics Price Performance

Shares of Cytokinetics stock opened at $63.86 on Friday. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The firm has a market cap of $7.81 billion, a PE ratio of -10.15 and a beta of 0.58. The company has a 50 day simple moving average of $62.99 and a two-hundred day simple moving average of $49.31.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to analysts’ expectations of $6.05 million. During the same quarter last year, the business posted ($1.36) EPS. The business’s quarterly revenue was up 318.1% compared to the same quarter last year. As a group, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval of Myqorzo (aficamten) turns Cytokinetics into a commercial‑stage cardiology biotech and establishes a new revenue runway — a principal driver of investor enthusiasm. Article Title
• Positive Sentiment: Multiple brokers raised price targets or reiterated Buy/Outperform views (examples: Citizens/JMP raised its PT to $88; Morgan Stanley maintained an overweight), supporting further upside expectations. Article Title
• Positive Sentiment: Unusually high call‑option volume suggests traders are positioning for additional near‑term upside. Article Title
• Positive Sentiment: Institutional accumulation reported in recent quarters (new and increased stakes by several funds) provides a supportive ownership base for the rally. Article Title
• Neutral Sentiment: Needham and other brokers reiterated positive ratings (Needham maintained its Buy) — supportive but largely reaffirmative rather than new catalysts. Article Title
• Neutral Sentiment: Reported short‑interest data in December shows zero shares (likely a reporting/data anomaly), so short‑interest signals are currently uninformative.
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at about $66.14 (Dec. 22), trimming his stake ~38% — a potential near‑term negative for sentiment. SEC Filing
• Negative Sentiment: HC Wainwright trimmed Q4 and FY2025 EPS forecasts slightly (small downward revisions to losses per share), signaling modestly weaker near‑term profitability expectations despite maintaining a Buy and a $136 target. Article Title

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CYTK shares. The Goldman Sachs Group set a $95.00 price objective on Cytokinetics and gave the company a “buy” rating in a research report on Thursday, December 18th. Evercore ISI increased their price target on shares of Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, September 3rd. UBS Group restated a “neutral” rating and issued a $61.00 price objective on shares of Cytokinetics in a report on Monday, December 1st. Stifel Nicolaus increased their target price on shares of Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley lifted their target price on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research report on Monday. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics has an average rating of “Moderate Buy” and an average price target of $83.61.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. UMB Bank n.a. lifted its holdings in Cytokinetics by 10.6% in the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 169 shares during the period. CIBC Private Wealth Group LLC increased its position in shares of Cytokinetics by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 261 shares during the period. Fifth Third Bancorp increased its position in shares of Cytokinetics by 32.3% during the third quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 262 shares during the period. Teacher Retirement System of Texas raised its stake in Cytokinetics by 1.1% in the second quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock worth $1,008,000 after buying an additional 341 shares in the last quarter. Finally, KLP Kapitalforvaltning AS lifted its holdings in Cytokinetics by 1.7% in the second quarter. KLP Kapitalforvaltning AS now owns 24,000 shares of the biopharmaceutical company’s stock worth $793,000 after buying an additional 400 shares during the period.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.